Durgical
EN
Open the app

MET inhibitors

Oral selective inhibitors of the MET kinase for non-small cell lung cancer with MET exon 14 skipping. Oedema is the hallmark effect.

Updated

What they are

Capmatinib and tepotinib treat metastatic non-small cell lung cancer with MET exon 14 skipping. Crizotinib (an ALK/ROS1 inhibitor) also blocks MET, and amivantamab targets MET from outside the cell.

Mechanism of action

MET is the receptor for hepatocyte growth factor. Exon 14 encodes the region that lets the cell tag MET for destruction; when it is skipped, MET piles up and signals constantly through RAS–MAPK and PI3K pathways. Selective MET inhibitors bind the ATP site and switch this signal off.

Target: MET (hepatocyte growth factor receptor) tyrosine kinase

Drugs in this class

Others in the class

  • Savolitinib
  • Crizotinib (also MET)
  • Amivantamab (anti-EGFR/MET antibody)

Test yourself

Think of the answer, then tap the question to see it.

What does MET exon 14 skipping do to the receptor?

It removes the degradation signal, so MET accumulates and signals constantly.

What is the most common adverse effect of MET inhibitors?

Peripheral oedema.

Which two selective MET inhibitors have DurgiPedia pages?

Capmatinib and tepotinib.

Add to my cards (3)

More Pharmacology questions →

← All of pharmacology

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: ATCDDD - ATC/DDD Index (WHO Collaborating Centre for Drug Statistics Methodology, 2026); Capmatinib: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2022); Tepotinib: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2024).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.